Analyst Rating Update on EXACT Sciences Corporation (EXAS)

EXACT Sciences Corporation (EXAS) : Zacks Investment Research ranks EXACT Sciences Corporation (EXAS) as 2, which is a Buy recommendation. 5 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 10 research analysts is 2, which indicates as a Buy.

EXACT Sciences Corporation (EXAS) : Average target price received by EXACT Sciences Corporation (EXAS) is $15.33 with an expected standard deviation of $5.52. The most aggressive target on the stock is $26, whereas the most downbeat target is $8. 9 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Jefferies maintains its ratings on EXACT Sciences Corporation (NASDAQ:EXAS). In the latest research report, Jefferies raises the target price from $13 per share to $20 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on July 27, 2016.


EXACT Sciences Corporation (NASDAQ:EXAS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $17.70 and $17.51 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $18.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $18.29, notching a gain of 3.04% for the day. The total traded volume was 3,271,637 . The stock had closed at $17.75 on the previous day.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.